Tempest Therapeutics, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Director John D. Yee was granted 25,000 stock options in Tempest Therapeutics, Inc. as part of a standard equity compensation package.
NASDAQ
Director William Drake Richey was granted 25,000 stock options in Tempest Therapeutics, Inc. as part of a standard equity incentive.
NASDAQ
Tempest Therapeutics Corporate Controller Justin Trojanowski acquired employee stock options, with vesting scheduled to begin in March 2027.
NASDAQ
Tempest Therapeutics' Chief Financial Officer, Nicholas Maestas, was granted employee stock options for 140,000 shares.
NASDAQ
Tempest Therapeutics' CEO and President, Matthew Angel, acquired 231,482 shares of common stock for $2.16 per share, signaling strong insider confidence.
NASDAQ
Tempest Therapeutics CEO and President Matthew Angel was granted 269,621 employee stock options with an exercise price of $2.38, vesting over four years.
NASDAQ
Tempest Therapeutics director Ronit Simantov was granted 1,230 stock options with an exercise price of $2.94, vesting by early 2027.
NASDAQ
Tempest Therapeutics director Geoffrey Nichol received 1,230 stock options with a $2.94 exercise price, vesting by early 2027.
NASDAQ
Tempest Therapeutics Director Michael Raab acquired 1,230 stock options with an exercise price of $2.94, vesting by early 2027.
NASDAQ
Tempest Therapeutics director Christine A. Pellizzari was granted 1,230 stock options with an exercise price of $2.94.
NASDAQ
Stephen R. Brady, President and CEO of Tempest Therapeutics, Inc., acquired 550,000 stock options on January 2, 2025, according to a Form 4 filing with the SEC.
NASDAQ
Tempest Therapeutics' Chief Medical Officer, Samuel Whiting, was granted 270,000 stock options on January 2, 2025, according to a recent SEC filing.
NASDAQ
Tempest Therapeutics' Corporate Controller, Justin Trojanowski, was granted 30,000 stock options on January 2, 2025, according to a recent SEC filing.
NASDAQ
Tempest Therapeutics' Chief Financial Officer, Nicholas Maestas, was granted 200,000 employee stock options on January 2, 2025.
NASDAQ
Versant Venture Capital VI, L.P. and related entities sold shares of Tempest Therapeutics (TPST) in two transactions on August 8 and August 12, 2024.
NASDAQ
Tempest Therapeutics' CEO, Stephen R. Brady, purchased 35,000 shares of common stock at $2.11 per share on July 3, 2024.
NASDAQ
Samuel Whiting, Chief Medical Officer of Tempest Therapeutics, recently purchased 4,672 shares of common stock at a price of $2.13 per share.
NASDAQ
Justin Trojanowski, Corporate Controller of Tempest Therapeutics, recently purchased 7,500 shares of TPST common stock at $2.16 per share, increasing his total holdings.
NASDAQ
Christine Pellizzari, a director at Tempest Therapeutics, acquired stock options for 16,000 shares on June 13, 2024.
NASDAQ
Director Geoffrey Nichol acquired stock options for 16,000 shares of Tempest Therapeutics, Inc. at an exercise price of $3.03 on June 13, 2024.
NASDAQ
Director Ronit Simantov acquired stock options for 16,000 shares of Tempest Therapeutics common stock on June 13, 2024.
NASDAQ
Director Michael Raab acquired stock options in Tempest Therapeutics, Inc. on June 13, 2024.